Latest Breaking News On - Eric schoen - Page 1 : comparemela.com

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants.‘Notice of.

Cassava Sciences : Corporate Presentation – First Quarter 2024 -March 25, 2024 at 09:36 am EDT

Corporate Overview First Quarter 2024 Forward-Looking Statements & Other Notices Cassava Sciences is in the business of new drug discovery.

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials.